VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

What symbol and exchange does Vertex Pharmaceuticals shares trade?

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

What is Vertex Pharmaceuticals stock price doing today?

As of February 9, 2026, VRTX stock price declined to $470.87 with 1,512,747 million shares trading.

What is Vertex Pharmaceuticals's Beta?

VRTX has a beta of 0.19, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.01 to the broad based SPY ETF.

How much is Vertex Pharmaceuticals worth?

VRTX has a market cap of $119.47 billion. This is considered a Large Cap stock.

How much money does Vertex Pharmaceuticals make?

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.80 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.45.

What is the highest and lowest price Vertex Pharmaceuticals traded in the last 3 year period?

In the last 3 years, VRTX traded as high as $519.88 and as low as $283.60.

What are the top ETFs holding Vertex Pharmaceuticals?

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

Is Vertex Pharmaceuticals (VRTX) a good investment?

VRTX has underperformed the market in the last year with a price return of -2.1% while the SPY ETF gained +15.7%. However, in the short term, VRTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.1% vs +3.8% return in SPY. But in the last 2 weeks, VRTX shares have been beat by the market, returning +0.5% compared to an SPY return of +0.7%.

What are the support and resistance levels for Vertex Pharmaceuticals (VRTX)?

VRTX support price is $468.86 and resistance is $486.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.